Allspring Global Investments
IBRX icon

Allspring Global Investments’s ImmunityBio IBRX Stock Holding History

Allspring Global Investments’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,189
Closed -$73.1K – 1914
2026
Q1 		$73.1K Buy
+10,189
New +$69.8K ﹤0.01% 1657
2022
Q2 		– Sell
-124,998
Closed -$701K – 2800
2022
Q1 		$701K Sell
124,998
-3,556
-3% -$21.8K ﹤0.01% 2072
2021
Q4 		$781K Buy
+128,554
New +$966K ﹤0.01% 2085

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Allspring Global Investments's IBRX Position: Q2 2026 in Review

Allspring Global Investments sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 10,189 shares — an estimated $73.1K sold.

Allspring Global Investments first reported a position in IBRX in Q4 2021 and held it in 3 quarters. The position peaked at $781K in Q4 2021. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Allspring Global Investments reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
  • Allspring Global Investments sold 10,189 ImmunityBio shares in Q2 2026, an estimated $73.1K.
  • Allspring Global Investments first reported a position in ImmunityBio in Q4 2021 and held it in 3 quarters.
  • Allspring Global Investments's ImmunityBio position peaked at $781K in Q4 2021.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.